In situ CAR-T cell therapy targeting multiple… · relapsed/refractory multiple myeloma Phase I clinical trial

According to official protocol filings (target population synthesized by CMDN from study details, not an official registry field), this study is primarily designed for patients with [Relapsed/refractory]. Eligibility requires verified clinical confirmation by investigators regarding prior lines of therapy, active disease biomarkers, and performance status.

According to verified protocol filings, key eligibility thresholds include: age ≥ 18 years, ECOG performance status ≤ 2. The study specifies 14 inclusion and 8 exclusion criteria covering detailed organ function and medical history. Final enrollment confirmation is determined by investigators at participating hospital trial centers.

The core therapeutic target or investigational mechanism is [In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5]. It aims to selectively eradicate clonal plasma cells or redirect anti-tumor immune responses, representing an active area of precision hematology research.

This study is registered as a [Phase I] clinical trial. The protocol is conducted under rigorous ethical and Good Clinical Practice (GCP) oversight approved by institutional ethics committees.

This is an international multi-centre study with 0 study centres in China and 1 overseas centres. The lead institution is [Cancer Hospital, Chinese Academy of Medical Sciences]. Prominent sites include Cancer Hospital, Chinese Academy of Medical Sciences. Eligible domestic patients can seek screening at the nearest participating centre.

The official public registration identifier for this protocol is [TM20260016] (OTHER). Patients and researchers can verify registration and ethical authorizations directly through the study hospital ethics committee or designated registry.